Vertex Pharma (VRTX) Tops Q2 EPS by 11c; Raises Outlook

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Vertex Pharma (VRTX) Tops Q2 EPS by 11c; Raises Outlook

Vertex Reports Second Quarter 2022 Financial Results

August 4, 2022 4:01 PM EDT

Product revenues of $2.20 billion, a 22% increase compared to Q2 2021

Company raises full year 2022 product revenue guidance to $8.6 to $8.8 billion

Recent exa-cel and VX-880 clinical data presentations demonstrate transformative potential for patients with sickle cell disease, beta thalassemia and type 1 diabetes

Multiple clinical programs entering or progressing through late-stage clinical development

BOSTON--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the second quarter ended June 30, 2022 and updated its full year 2022 financial guidance.

With... More